Scilex Holding Co SCLX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $1.74
- Day Range
- $1.61–1.78
- 52-Week Range
- $1.61–16.81
- Bid/Ask
- $1.61 / $1.75
- Shares Outstanding
- 7.03M
- Market Cap
- $11.33M
- Volume/Avg
- 31,376 / 40,701
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.44
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Small Value
- Total Number of Employees
- 34
Valuation
Metric | SCLX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.44 |
Price/Cash Flow | — |
Price/Earnings
SCLX
Financial Strength
Metric | SCLX |
|---|---|
Quick Ratio | 0.05 |
Current Ratio | 0.07 |
Interest Coverage | −25.02 |
Quick Ratio
SCLX
Profitability
Metric | SCLX |
|---|---|
Return on Assets (Normalized) | −147.06% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
SCLX
Drug Manufacturers - General Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Eli Lilly and Co LLY | LOCK|&@^BX&M> | LOCK|Q%x | $1T | |||
| Johnson & Johnson JNJ | LOCK|&Q!wrKN | LOCK|^j? | $676B | |||
| AbbVie Inc ABBV | LOCK|zqVt&J | LOCK|!>% | $519B | |||
| Roche Holding AG ADR RHHBY | LOCK|df&qg!$@ | LOCK|JG | $392B | |||
| Merck & Co Inc MRK | LOCK|bx#PhW | LOCK|C>$ | $365B | |||
| Novartis AG ADR NVS | LOCK|&n^n?hX@ | LOCK|rzz | $310B | |||
| AstraZeneca PLC AZN | LOCK|tDJsJfkC | LOCK|#GQ | $289B | |||
| Amgen Inc AMGN | LOCK|>gbsGv> | LOCK|%d$ | $252B | |||
| Gilead Sciences Inc GILD | LOCK|fj$@$Np | LOCK|@M> | $212B | |||
| Novo Nordisk AS ADR NVO | LOCK|?$m<cT& | LOCK|z%& | $180B |
United States